Cell and Gene Outsourcing

  1. Particles In High Concentration Biotherapeutics 8/7/2025

    Examine advanced analytical solutions that detect, characterize, and mitigate particle formation in high-concentration biotherapeutics caused by protein aggregation and surfactant degradation.

  2. Oligonucleotide Discovery And Development 8/7/2025

    Observe how comprehensive R&D support advances therapeutic oligonucleotides from discovery through commercialization with tailored formulation development services across multiple modalities and delivery platforms.

  3. Best Practices For Regulatory Excellence In Clinical Research 8/7/2025

    Observe how GCLP can integrate ethical and technical standards to ensure reliable, compliant clinical trial data and optimize laboratory operations across sponsors, CROs, and partners.

  4. How Compliance-Driven CDMOs Win Sponsor Contracts 8/6/2025

    Discover how evolving global regulations are reshaping CDMO strategy. and how digital infrastructure helps manufacturers stay audit-ready, build sponsor trust, and turn compliance into an advantage.

  5. Alzheimer's Imaging, Simplified 8/5/2025

    Find what you need to move your Alzheimer’s research forward faster, with antibodies to 95% of core AD genes validated in imaging applications with human samples.

  6. Custom Antibody Development And Characterization Services 8/5/2025

    Our in-house custom antibody delivery team has a proven track record of developing antibodies to challenging targets with exacting specifications.

  7. Accelerate Path To Clinic With CMC Consultation Services 8/5/2025

    In today’s competitive and capital-constrained cell and gene therapy environment, early decisions around Chemistry, Manufacturing, and Controls (CMC) can make or break a therapy's timeline, cost-efficiency, and eventual approval. Yet many emerging cell therapy companies struggle with CMC strategy until it becomes a bottleneck.

  8. Optimizing Cell Therapy Analytics Through DoE Methodologies 8/4/2025

    Design of Experiment (DoE) methods streamline the development of robust, phase-appropriate potency and functional assays, ensuring testing that supports scalable cell therapy development.

  9. Lentiviral Vectors: The Key To Cell And Gene Therapy Success 7/30/2025

    Lentiviral vector manufacturing is complex and highly regulated, which is why a specialized CDMO is required to ensure safe, scalable, and compliant production from early development to commercialization.

  10. Blueprint To Modernizing CDMO Manufacturing Operations 7/29/2025

    Industry 4.0 is revolutionizing CDMOs and CMOs. Find out how AI, IIoT, and automation are driving smarter, faster, and more compliant manufacturing to ensure agility, precision, and innovation.